Otonomy is a San Diego-based biopharmaceutical company that specializes in developing treatments for neurotology. The company is currently working on three main therapeutics, including OTO-313, a drug in Phase II clinical trials to treat tinnitus. Otonomy also has license agreements and collaborations with various organizations to develop and commercialize treatments for hearing loss.